Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Ironwood Pharmaceuticals (IRWD) Shares Outstanding (2016 - 2026)

Ironwood Pharmaceuticals' Shares Outstanding history spans 17 years, with the latest figure at $163.1 million for Q4 2025.

  • On a quarterly basis, Shares Outstanding rose 1.78% to $163.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $163.1 million, a 1.78% increase, with the full-year FY2025 number at $163.1 million, up 1.78% from a year prior.
  • Shares Outstanding hit $163.1 million in Q4 2025 for Ironwood Pharmaceuticals, roughly flat from $162.7 million in the prior quarter.
  • Over the last five years, Shares Outstanding for IRWD hit a ceiling of $163.4 million in Q3 2021 and a floor of $153.2 million in Q2 2022.
  • Historically, Shares Outstanding has averaged $158.9 million across 5 years, with a median of $159.9 million in 2024.
  • Biggest five-year swings in Shares Outstanding: decreased 6.17% in 2022 and later increased 2.49% in 2024.
  • Tracing IRWD's Shares Outstanding over 5 years: stood at $162.0 million in 2021, then dropped by 4.94% to $154.0 million in 2022, then increased by 1.51% to $156.4 million in 2023, then grew by 2.46% to $160.2 million in 2024, then grew by 1.78% to $163.1 million in 2025.
  • Business Quant data shows Shares Outstanding for IRWD at $163.1 million in Q4 2025, $162.7 million in Q3 2025, and $162.4 million in Q2 2025.